ClinicalTrials.Veeva

Menu

Prevention and Early Identification for High Risk Youth in School-based Clinics

Cambridge Health Alliance logo

Cambridge Health Alliance

Status and phase

Completed
Phase 1

Conditions

Resilience, Psychological
Screening
Adolescent Well Being
Health Equity
Community Mental Health Services

Treatments

Behavioral: COPE2Thrive
Genetic: Usual care

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT04935710
P50MH126283 (U.S. NIH Grant/Contract)
ALACRITY eSToRY R34 #1

Details and patient eligibility

About

The proposed research project provides a novel approach to screening, early assessment, and preventive interventions for high-risk youth in racial/ethnic/linguistically (REL)-diverse communities.

  • The investigators assess a health promotion intervention as a way of reducing treatment disparities in REL-minority youth. This population is underrepresented in child psychiatry research. It is often excluded from clinical trials of medication or therapy because of challenges with transportation, literacy, resources, or other issues.
  • The study will take place during or following a healthcare crisis and economic recession, making findings relevant to understanding the mechanisms by which hardship translates into youth mental illness.
  • The innovative integration of online screening into school-based clinics and community-based settings in REL-minority communities is made possible by the combination of access to a new technology (CAT) in the context of a learning health community serving a REL-minority population.
  • Empirical research on the impact of a resilience-based prevention intervention in youth and youth at risk is both innovative and much needed during this period of health, social and economic crisis.

Full description

Four hundred high school students will be screened for psychiatric symptoms and functional impairment using the Kiddie Computerized Adaptive Testing (K-CAT) and the Weiss Functional Impairment Rating Scale - Self Report (WFIRS-S) in CHA's catchment area (Cambridge, Chelsea, Everett, Malden, Revere, Somerville, Winthrop. Students will be classified into three tiers: normal, at risk, and clinical . The cut off scores that differentiate the tiers are drawn from the ROC values generated by the psychometrics of the measures themselves as follows:

  • Tier 1: K-CAT Normal & WFIRS <0.8 - >1.0 (T <1SD).
  • Tier 2: K-CAT Mild & WFIRS 0.8 - >1.0, K-CAT Moderate & WFIRS 0.8 - 1.0 (T between 1 and 1.5 SD), K-CAT Severe & WFIRS 0.8 - 1.0 (T between 1 and 1.5 SD)
  • Tier 3: K-CAT Moderate & WFIRS >1.0 (T >1.5 SD), K-CAT Severe & WFIRS >1.0 (T >1.5 SD) If patients are symptomatic but not functionally impaired, status is determined by function because symptoms without impairment do not necessarily warrant intervention. If the patient is impaired but not symptomatic, the threshold is determined by symptoms because the patient may be impaired from factors other than the diagnosis. These scores are based on the results of the most severe module of either the K-CAT or the WFIRS. .All students will be eligible to participate in C2T, independent of how they are classified by Tier, unless they meet one of the exclusion criteria. Tier 3 will be informed that the participants' responses suggest that the participants are experiencing some symptoms which are causing them difficulty. As long as the participants are not assessed as critical imminent risk, Tier 3 will also be invited to participate in C2T.

A stepped wedge design with 3 clusters of 36 students each will be used to group students into clusters based on rolling recruitment into COPE2Thrive. The stepped wedge design assigns a random cluster to be switched from the control group to the C2T intervention group at either one, two, or three-week intervals starting at week 1 and ending at week 23 of the study.

Enrollment

219 patients

Sex

All

Ages

12 to 24 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

  • High school students in CHA's catchment area (Cambridge, Chelsea, Everett, Malden, Revere, Somerville, Winthrop)
  • Youth who are fluent in English, Haitian Creole, Portuguese, or Spanish.
  • Youth who experience at least some symptoms, defined as a K-CAT-S score (from Aim 1) of moderate on at least one diagnosis with at least mild functional impairment. Patients with more severe symptoms or functional impairment or who do not meet the exclusion criteria are also eligible.

Inclusion Criteria for COPE2Thrive:

  • High school students in CHA's catchment area (Cambridge, Chelsea, Everett, Malden, Revere, Somerville, Winthrop)
  • Youth who are fluent in English, Haitian-Creole, Portuguese, or Spanish.
  • Youth who have completed WFIRS and K-CAT, and who do not meet the exclusion criteria.

Exclusion Criteria:

  • 12th-graders will be excluded from the COPE2Thrive program since the participants will not be available for the study's duration.
  • Students who are already receiving behavioral health care.
  • Students who are considered to be seriously suicidal and in need of urgent care, in which case the participants would be ineligible based on the fact that the participants will be receiving behavioral health care.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

219 participants in 2 patient groups

R34#1 Aim 2 COPE2Thrive Intervention
Experimental group
Description:
Randomly clustered youth who have completed the screening will be randomized to receive a resilience based digital intervention, COPE2Thrive.
Treatment:
Behavioral: COPE2Thrive
Control arm
Active Comparator group
Description:
The comparator arm is treatment as usual. For each monthly crossover, 12 students in a cluster are eligible to receive C2T in a stepped wedge study design. Student outcomes prior to receiving C2T will be compared to outcomes after receiving C2T.
Treatment:
Genetic: Usual care

Trial contacts and locations

5

Loading...

Central trial contact

Margaret D Weiss, MD PhD; Eleanor C Richards, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems